Condition 1: Obesity. Condition 2: Overweight. Obesity, unspecified Overweight or localised adiposity
Conditions
Interventions
Intervention 1: Intervention group: each volunteer will take 2000 mg daily (one capsule 30 minutes before breakfast, two capsules 30 minutes before lunch and, one capsule 30 minutes before dinner) dru
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Female only Age 20 to 40 years Women over the age of 40 will be included in the study if they have a normal mammogram. BMI between 25 and 34.9 kg / m2
Exclusion criteria
Exclusion criteria: Pregnancy and lactation Menopause Hypermenorrhea, Menorrhagia Regular use of teas or other herbal medicines Smoking or alcohol consumption History of any types of malignancies Asthma History of any allergies History of any hormonal disorders History of chronic liver, heart, kidney, thyroid diseases, diabetes mellitus, hypertension, infectious diseases Family history of Brest or endometrial cancer in first-degree relatives Regular use of acetaminophen (paracetamol) or anticoagulants or antiplatelet drugs such as aspirin, warfarin, heparin and ... Use of weight loss diets or weight loss drugs during the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At the beginning of the study (before the intervention), 4 weeks and 8 weeks after the intervention. Method of measurement: Digital scales.;Waist circumference size. Timepoint: At the beginning of the study (before the intervention), 4 weeks and 8 weeks after the intervention. Method of measurement: Tape measure.;Hip circumference size. Timepoint: At the beginning of the study (before the intervention), 4 weeks and 8 weeks after the intervention. Method of measurement: Tape measure.;Body Mass Index (BMI). Timepoint: At the beginning of the study (before the intervention), 4 weeks and 8 weeks after the intervention. Method of measurement: Ratio of weight to height squared. | — |
Secondary
| Measure | Time frame |
|---|---|
| The dietary intake. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Dietary intake questionnaire.;Fasting blood glucose. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum Triglyceride. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum High Density Lipo protein(HDL). Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum low density lipoprotein level. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Friedwalt formula.;Serum Cholestrole. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Laboratory measurement method auto analyzer.;Alanine transaminase. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Laboratory measurement method auto analyzer.;Aspartate aminotransferase. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Laboratory measurement method auto analyzer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Aghabeiglooei
Tehran University of Medical Sciences
Outcome results
None listed